CA-SCIENTIST.COM
2.12.2020 10:35:04 CET | Business Wire | Press release
Scientist.com, the healthcare industry’s leading marketplace for outsourced research, has partnered with Enhancing Quality In Preclinical Data (EQIPD) to help define and improve data quality within preclinical research. A self-certification questionnaire is now accessible via Scientist.com’s award-winning compliance solution COMPLi®, allowing global suppliers to self-certify prior to working with biopharma research organizations. With this self-certification, suppliers demonstrate their data integrity processes and procedures to potential clients.
“EQIPD’s holistic approach to tackling the challenges related to data quality within preclinical research aligns with our COMPLi standards, which provides researchers with the proper due diligence necessary to source from suppliers of preclinical services,” stated Matt McLoughlin, VP of Categories & Compliance. “We are working with EQIPD to ensure data integrity is at the heart of research.”
Currently, there are no globally accepted quality standards when it comes to reporting data generated by preclinical research. To define and implement such standards EQIPD has formed a consortium of key stakeholders that includes large pharma (including a number of current Scientist.com clients), biotech companies, academia and compliance solutions. The consortium works closely with Stakeholder Group members such as Scientist.com. EQIPD is looking to develop best practices that can be shared across R&D in the life sciences.
“Use of the EQIPD-derived tools by stakeholders such as Scientist.com enables EQIPD to deliver its mission of improving data integrity standards across the global research community,” stated Anton Bespalov of PAASP, an EQIPD consortium member. “Their COMPLi platform can increase visibility to our work and ensure it aligns completely with the goals of EQIPD moving forward.”
“Including a self-certification questionnaire, based on the EQIPD standard, within COMPLi, streamlines and harmonises the data quality and data integrity due diligence process applied by biopharma research organizations during the on-boarding of preclinical service suppliers,” stated Sandrine Bongiovanni of Novartis Pharma AG.
Research organizations looking to self-certify or learn more about COMPLi can visit https://www.scientist.com/compli/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook , and Instagram
About EQIPD
The Enhancing Quality in Preclinical Data consortium (EQIPD; previously "European Quality in Preclinical Data") was founded in 2017 by 29 academic institutions, pharmaceutical companies, and SMEs from 8 countries (https://quality-preclinical-data.eu ).
Supported through the European Union’s Innovative Medicines Initiative (IMI), major deliverables of the EQIPD consortium were the development of a novel preclinical research quality system that could be applied in both the public and private sectors, and the generation of online training capacity in good research practice.
The consortium works closely with a large group of associated collaborators, advisors and stakeholders drawn from nearly 100 organizations in Europe and the US and including research institutions, publishers, funders, learned societies and professional societies.
Follow EQIPD on social media:
https://www.facebook.com/EQIPD/
https://twitter.com/EQIPD
https://www.linkedin.com/groups/12074241/profile
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005416/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year14.5.2026 06:01:00 CEST | Press release
AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/ In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom